Edwards Lifesciences Hemosphere

Edwards Lifesciences, Wolfe

Edwards Lifesciences downgraded at Wolfe on TAVR worries

Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device maker, citing concerns over its prospects in the market for Transcatheter Aortic Valve Replacement (TAVR).

Business Insider · 1d

Edwards Lifesciences downgraded to Underperform at Wolfe Research

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core

Investing.com on MSN · 1d

Wolfe Research cuts Edwards Lifesciences stock rating to Underperform

Wolfe Research adjusted its perspective on Edwards Lifesciences (NYSE:EW) shares, downgrading its rating from Peerperform to Underperform. The firm also set a price target of $60.00 for the medical technology company's stock,

Citi Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

Citi analyst Joanne Wuensch maintained a Buy rating on Edwards Lifesciences (EW – Research Report) today. The company’s shares closed yesterday ...

Yahoo Finance1mon

Edwards Lifesciences Outlines Vision For Growth At Investor Conference

On Wednesday, during its annual investor conference, Edwards Lifesciences Corporation (NYSE:EW) detailed its strategy for sustained long-term growth and innovations in structural heart therapies.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Edwards Lifesciences, Wolfe

Trending now